4benchmark.com  
 
HOME | MEDICINES | RX DRUGS | RESOURCES | DIRECTORY | SITE MAP

 
   
 
The empire strikes back: innovators releasing generic drugs

The empire strikes back: innovators releasing generic drugs

A new study confirms the trend toward innovator pharmaceutical companies switching their brand names to generics as they come off patent.

The report, "Combating Generics: Pharmaceutical Brand Defense" released last week by Cutting Edge Information (Durham, NC, www.cuttingedgeinfo.com), notes that most innovator companies hold off making the move until a generic company announces its intentions to enter the market. The innovator then switches into high gear to reach the market first, taking advantage of its existing resources to fix the generic drug's price and claim a portion of generic revenues. According to the report, generic drug prescriptions constitute 50% of all US drug prescriptions.

Cutting Edge reports that "in the next five years, participating companies will expose an average $541.7 million in aggregate revenue to generics competitors."

"If a pharmaceutical company's generic subsidiary can be first-to-market, the company essentially retains devalued market share for its off-patent drug," states Ion Hess, senior analyst for Cutting Edge Information in the company's statement. "With patents for drugs such as Prevacid and Zoloft set to expire in July and December 2005, respectively, generic drug makers stand poised to enter the market with competitive generic products. It will be interesting to see which generic defense strategies these brands utilize."
Health Articles

Economic consequences of underuse of generic

Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans - Primary Care and Workforce Issues - IllustrationBrand name drugs are typically more expensive than generic versions of the same drug, which in general have identical

Pharmaceutical costs weighing heavily on

Pharmaceutical costs weighing heavily on formulas, study findsBOSTON -- Stung by double-digit price increases on prescription medicines, health plans increasingly are taking cost into account when deciding which new

Pediatric Rx spending spending tops the growth

Pediatric Rx spending spending tops the growth chart - Chain Pharmacy - 2002 Drug Trend Report; prescription drugs - Brief Article - Statistical Data IncludedFRANKLIN LAKES, N.J.--Spending on prescription drugs for infants, children, adolescents and young adults has mushroomed 85 percent over the last five years,

Have pharmaceutical companies been unfair to

Have pharmaceutical companies been unfair to American consumers? Yes: Americans should not have to pay significantly more for the same prescription drugs as our friends in Canada and Europe - SYMPOSIUMThere is little question that increasing health-care costs are a problem that affects all Americans. Small businesses have difficulty hiring new employees because they can't afford to provide health insurance.